Evidence mapPaperPMID 39594641Full record

SynthesisCells2024

Metabolic Dysfunction-Associated Steatotic Liver Disease and Alcohol-Associated Liver Disease: Liver DNA Methylation Analysis-A Systematic Review.

Daniela Stols-Gonçalves, Abraham S Meijnikman, Luca Schiliró Tristão, Clara Lucato Dos Santos, Nerissa P Denswil, Joanne Verheij, Wanderley M Bernardo, Max Nieuwdorp

Abstract readSystematic Review
In one paragraph

Synthesis in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniela Stols-GonçalvesDepartment of Internal and Vascular Medicine, Amsterdam University Medical Centre, Meibergdreef 9 (Room A01-112), 1105 AZ Amsterdam, The Netherlands.
Abraham S MeijnikmanDepartment of Internal and Vascular Medicine, Amsterdam University Medical Centre, Meibergdreef 9 (Room A01-112), 1105 AZ Amsterdam, The Netherlands.
Luca Schiliró TristãoDepartment of Evidence-Based Medicine, Faculdade de Ciências Médicas de Santos-Lusiada University Center, Santos 11050-071, SP, Brazil.ORCID 0000-0002-7197-0915
Clara Lucato Dos SantosDepartment of Evidence-Based Medicine, Faculdade de Ciências Médicas de Santos-Lusiada University Center, Santos 11050-071, SP, Brazil.
Nerissa P DenswilMedical Library, Amsterdam University Medical Centre, University of Amsterdam, 1012 WP Amsterdam, The Netherlands.ORCID 0000-0002-5420-3909
Joanne VerheijDepartment of Pathology, Amsterdam University Medical Centre, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0003-1283-630X
Wanderley M BernardoDepartment of Evidence-Based Medicine, Faculdade de Ciências Médicas de Santos-Lusiada University Center, Santos 11050-071, SP, Brazil.ORCID 0000-0002-8597-5207
Max NieuwdorpDepartment of Internal and Vascular Medicine, Amsterdam University Medical Centre, Meibergdreef 9 (Room A01-112), 1105 AZ Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated liver disease (MASLD) and alcohol-associated liver disease (ALD) are among the leading causes of liver disease worldwide. The exact roles of epigenetic factors in both diseases remains largely unknown. In this context, liver DNA methylation remains a field that requires further exploration and understanding.

methodsWe performed a systematic review of liver DNA methylation in humans with MASLD or ALD using Ovid MEDLINE, Ovid Embase, and Cochrane Library. We included human studies where liver DNA methylation was assessed in patients with MASLD and/or ALD. The Rayyan platform was used to select studies. Risk of bias was assessed with the "risk of bias in non-randomized studies of interventions" tool, ROBINS-I. We performed pathway analysis using the most important differentially methylated genes selected in each article.

resultsFifteen articles were included in this systematic review. The risk of bias was moderate to serious in all articles and bias due to confounding and patient selection was high. Sixteen common pathways, containing differentially methylated genes, including cancer pathways, were identified in both diseases.

conclusionsThere are common pathways, containing differentially methylated genes, in ALD and MASLD, such as pathways in cancer and peroxisome proliferator-activated receptor (PPAR) signaling pathways. In MASLD, the insulin signaling pathway is one of the most important, and in ALD, the MAPK signaling pathway is the most important. Our study adds one more piece to the puzzle of the mechanisms involved in steatotic liver disease.

Indexed as

DNA MethylationLiverLiver Diseases, AlcoholicEpigenesis, GeneticFatty LiverHumansMetabolic Diseasesalcohol-associated liver diseaseepigeneticsinsulin resistancemetabolic dysfunction-associated steatotic liver diseaseperoxisome proliferator-activated receptor

Identifiers

PMID39594641
PMCPMC11592595

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.